Share Options and Reward Shares - As of December 31, 2024, the total number of ordinary shares available for issuance under the share option scheme is 9,213,705 shares, accounting for 10% of the company's issued shares[4] - No share options were granted under the share option scheme for the years ended December 31, 2024, and December 31, 2023[4] - The company granted 3,900,000 reward shares to employees on April 15, 2024, with a fair value of HKD 0.37 per share[6] - The reward shares will vest to each grantee one year after the grant date[8] - The company clarifies that the share option scheme adopted on June 15, 2012, has expired in 2022, and no ordinary shares are available for issuance under this scheme[4] Financial Reporting and Governance - The company’s financial statements are prepared in accordance with the accounting standards and policies adopted[8] - The announcement serves as a supplement to the annual report for the year ended December 31, 2024, and should be read in conjunction with it[6] - The board of directors includes both executive and independent non-executive members, ensuring diverse governance[7] Business Developments - The company has not disclosed any new product developments or market expansion strategies in this announcement[5] - There are no reported mergers or acquisitions in the current financial year[5]
中科生物(01237) - 2025 - 年度业绩